Related references
Note: Only part of the references are listed.Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia
Naval Daver et al.
LEUKEMIA RESEARCH (2014)
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
Matthew Hoffmann et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
Ling Lu et al.
MICROVASCULAR RESEARCH (2009)
Immunomodulatory drugs Revlimid (R) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Dan Zhu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Chiral inversion of the second generation IMiD™ CC-4047 (ACTIMID™) in human plasma and phosphate-buffered saline
SK Teo et al.
CHIRALITY (2003)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
D Gupta et al.
LEUKEMIA (2001)
Share Paper
